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ABSTRACT
Pus samples were prospectively collected from
patients with Staphylococcus aureus skin infections
and tested for Panton–Valentine leukocidin
(PVL). PVL was detected at concentrations that
were toxic for rabbit skin in all specimens from
patients infected with strains harbouring PVL
genes.
Keywords ELISA, Panton–Valentine leukocidin, quan-
tiﬁcation, skin infection, Staphylococcus aureus
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Staphylococcus aureus is an important human
pathogen that expresses a variety of exoproteins,
including Panton–Valentine leukocidin (PVL) [1].
PVL genes are carried by community-acquired
methicillin-resistant S. aureus (CA-MRSA) clones
that are spreading throughout the world [2,3].
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PVL is a bi-component pore-forming exotoxin
that targets cells of the immune system, e.g.
polymorphonuclear neutrophils, monocytes and
macrophages [4]. In vitro, PVL kills human and
rabbit polymorphonuclear neutrophils through
necrosis, whereas intradermal PVL injection
in rabbits provokes skin erythema followed by
dose-dependent necrosis [4,5].
PVL production has been epidemiologically
linked to speciﬁc human S. aureus infections,
such as primary skin and soft tissue disease,
severe necrotizing pneumonia, and severe bone
and joint infections [6–8], regardless of methicil-
lin sensitivity. This suggests that PVL may play a
role in infections due to S. aureus strains har-
bouring PVL genes, but there is still no direct
evidence that PVL is produced at toxic concen-
trations in vivo.
The aim of this study was to determine whether
PVL is produced in human S. aureus abscesses and,
if so, whether it reaches potentially toxic concen-
trations. Pus samples (‡300 lL)were prospectively
collected from patients with furuncles or abscesses
(cutaneous or subcutaneous) during a 6-month
period at Edouard Herriot Hospital, Lyon, France.
Pus was tested for S. aureus, and aliquots were
stored at –20C for PVL quantiﬁcation. S. aureus
was identiﬁed on the basis of colony and cell
morphology, coagulase testing with rabbit plasma
(bioMe´rieux, Marcy l’Etoile, France), and the
Staphyslide agglutination test (bioMe´rieux). Geno-
mic DNA was extracted for PCR analysis with
a standard procedure, and its concentration
was estimated spectrophotometrically. Sequences
speciﬁc for the PVL genes (lukS-PV and lukF-PV,
forming the luk-PV operon) and the mecA gene
(coding for methicillin resistance) were detected
by PCR, and multilocus sequence typing of mecA-
positive and luk-PV-positive isolates was per-
formed as previously described [3]. In parallel,
pus samples positive for S. aureus (regardless of
luk-PV and mecA status) were blindly analysed in
duplicate with a solid-phase sandwich ELISA,
using a mouse monoclonal antibody and a rabbit
peroxidase-conjugated polyclonal F(ab)¢2 frag-
ment targeting LukS-PV, as recommended by the
supplier (R&D Immunoassays, BioMe´rieux,Marcy
l’Etoile, France). Brieﬂy, samples were thawed to
+4C, vortexed for 1 min, sterilized by 1 h of
heating at 94C, followed by cooling at +4C on
ice for 5 min, and centrifuged at 10 000 g for 5 min.
PVL quantiﬁcation was performed in the superna-
tant in duplicate. The ELISA detection limit of PVL
was 50 ng ⁄mL.
Pus from 41 patients was studied, and all
samples yielded S. aureus. Fifteen isolates were
positive for luk-PV according to PCR. One of these
15 isolates, of sequence type (ST) 80, was also
mecA-positive and belonged to the European CA-
MRSA clone. PVL was detected with ELISA in all
pus samples that grew luk-PV-positive isolates.
The PVL concentration ranged from 0.27 mg ⁄L to
over 2 mg ⁄L, and exceeded 1 mg ⁄L in the pus
that yielded the mecA-positive isolate (Table 1).
PVL was not detected by ELISA in any of the 26
samples from luk-PV-negative cases, including
Table 1. Panton–Valentine leukocidin (PVL) concentrations in human skin abscesses
Staphylococcus aureus isolates Skin abscesses
Number
luk-PV
detectiona
mecA gene
detectiona
PVL quantiﬁcation
by ELISA (mg ⁄L),
mean ± SD
Diameter
(mm)
Subcutaneous
extension
Fever,
dizziness
Recurrent
abscess
Antibiotic
before drainage
7 304 284 + ) 0.27 ± 0.05 26 Yes Yes No Amoxiclavb
7 666 159 + ) 0.41 ± 0.03 20 Yes No Yes No
7 182 102 + ) 0.42 ± 0.01 40 Yes Yes No Amoxiclav
7 203 017 + ) 0.92 ± 0.01 NR Yes No Yes Pristinamycin
6 022 246 + ) 0.99 ± 0.01 40 Yes Yes No No
6 154 246 + ) 1.17 ± 0.08 50 Yes Yes Yes Amoxiclav
7 161 319 + ) 1.19 ± 0.17 30 No No No No
6 101 308 + ) 1.34 ± 0.07 NR Yes No Yes No
7 162 452 + + 1.64 ± 0.08 51 Yes Yes No Amoxiclav
7 283 336 + ) 1.72 ± 0.28 10 Yes No No No
3 374 251 + ) 1.82 ± 0.08 35 No NR No No
6 216 012 + ) >1c NR Yes NR Yes No
7 341 038 + ) >1c NR NR NR NR NR
7 343 232 + ) >1c NR NR NR NR NR
7 233 478 + ) >1c 51 Yes Yes No No
NR, not recorded.
aThe luk-PV and mecA genes were detected by PCR as previously described [3].
bAmoxicillin–clavulanic acid.
cOwing to the small available volume of pus, the precise concentration of PVL could not be established.
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the two mecA-positive cases. In patients with skin
abscesses due to PVL-producing strains, a corre-
lation between abscess diameter and the occur-
rence of fever and dizziness was observed
(Mann–Whitney test, p 0.037). Abscess diameter
and PVL concentration were not statistically
correlated, due to the small population and to
missing information; however, only abscesses
with a PVL concentration above 1 mg ⁄L were
associated with large abscesses (diameter ‡5 cm),
suggesting a possible dose effect of PVL on
severity. No statistically signiﬁcant correlation
was found between the level of PVL and subcu-
taneous extension, recurrence, and the antibiotic
used before drainage.
These results clearly show that PVL is ex-
pressed in human skin abscesses due to S. aureus
strains harbouring luk-PV genes. Susceptibility to
PVL is species-dependent. Intradermal injection
of 30 ng of PVL induces oedema and erythema in
rabbits, and injection of 300 ng provokes wide-
spread and inﬁltrated erythema followed by skin
necrosis. In contrast, doses of up to 3 lg cause no
skin lesions in mice [5]. There are no correspond-
ing data concerning humans, but it is noteworthy
that human and rabbit leukocytes are sensitive to
similar concentrations of PVL [9], indirectly sug-
gesting that the levels observed here are probably
toxic for human skin.
Deleo et al. observed no differences in the
pathogenicity of PVL-positive and PVL-negative
isogenic strains of S. aureus in a mouse model of
skin abscess [10], possibly owing to the above-
mentioned relative insensitivity of mouse skin to
PVL at the concentrations reached in vivo.
The pus sample from the patient infected with
the most prevalent European clone of CA-MRSA
(the ST80 clone) contained a relatively high PVL
concentration. It was recently found that all luk-
PV-positive CA-MRSA strains actually produce
PVL [11], and that the clinical manifestations of
PVL-positive S. aureus infections are unrelated to
methicillin susceptibility [12]. Thus, the apparent
role of PVL in the pathophysiology of human skin
infections involves not only PVL-producing
MSSA, but also CA-MRSA.
This must be conﬁrmed, however, by studies
in areas with a high incidence of PVL-positive
CA-MRSA infections. The in vivo PVL production
by strains causing other infections, e.g. severe
necrotizing pneumonia [7] and severe bone and
joint infections [8], as well as the possible corre-
lation between PVL level and severity of disease,
should also be investigated.
Finally, these results further support the inclu-
sion of PVL in the list of S. aureus virulence
factors involved in the pathophysiology of human
skin infections.
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ABSTRACT
The seasonal variation in the incidence of invasive
pneumococcal disease is well recognized, but
little is known about its relationship with actual
changes in climatic parameters. In this 8-year
longitudinal population-based study in Denmark,
a harmonic sinusoidal regression model was
used to examine whether preceding changes in
climatic parameters corresponded with subse-
quent variations in the incidence of pneumococcal
bacteraemia, independently of seasonal variation.
The study shows that changes in temperature can
be used to closely predict peaks in the incidence
of pneumococcal bacteraemia with a time-lag of
16 days (95% CI 14–18 days), independently of a
strong seasonal pattern.
Keywords Bacteraemia, climate, incidence, pneumo-
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The seasonal variation in the incidence of invasive
pneumococcal disease, with a peak in incidence
during the winter months, is well recognized
[1–4]. However, few detailed studies of the
temporal relationship between actual climatic
changes and subsequent pneumococcal disease
are available. An 8-year longitudinal population-
based ecological study was undertaken in a
Danish county to examine whether changes in
climatic parameters could be used to predict
variations in the incidence of pneumococcal bac-
teraemia (PB).
Included were cases of PB that occurred from
January 1995 through December 2002 in North
Jutland County, Denmark, with an average pop-
ulation of 492 845 during the period of study,
corresponding to 9% of the total Danish popula-
tion. Patients with PB were identiﬁed in the
County Bacteraemia Registry, which comprises
blood culture results for the entire county [5]. PB
was deﬁned as an episode of clinical disease, with
Streptococcus pneumoniae detected by blood culture
[5].
Meteorological data, i.e. daily summaries from
a weather station corresponding to the area under
study, were obtained from the Danish Institute of
Agricultural Sciences. Daily mean values were
calculated for six pre-speciﬁed meteorological
variables: temperature (minimum, mean and
maximum), relative humidity, precipitation and
wind velocity. Monthly means and sums of these
variables were used in the data analysis.
A harmonic sinusoidal regression model [6]
was ﬁtted to estimate the phase difference in
months (converted to days by multiplying by 30)
between changes in each of the meteorological
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